The data, posted online by the journal Molecular Therapy, is the first from testing in patients of a Moderna vaccine. Dr. Graham said the preliminary data indicate Moderna’s mRNA vaccine technology can work, but he would like to see results from further testing in humans to confirm the technology’s safety. The company developed the H10N8 vaccine to demonstrate the viability of its approach, rather than to bring the vaccine itself to market, Moderna Chief Executive Stephane Bancel said. The vaccine used what Mr. Bancel described as an older technology to deliver the mRNA vaccine to the cells. The H10N8 vaccine used an older technology for delivering the mRNA to cells, which Moderna licensed from a Canadian company and which is the subject of a lawsuit.

Source: Wall Street Journal April 27, 2017 15:56 UTC